ANDRODERM (testosterone) by AbbVie is androgen receptor agonists [moa]. First approved in 1995.
Drug data last refreshed 2h ago · AI intelligence enriched 2d ago
ANDRODERM is a transdermal testosterone replacement therapy approved in 1995 for treating hypogonadism in males. It delivers testosterone via an extended-release film patch applied to the skin, working as an androgen receptor agonist to restore normal testosterone levels. The product addresses hormone deficiency in patients unable to produce adequate endogenous testosterone.
Product approaching loss of exclusivity with modest Part D spending ($3M) and ~4K claims, suggesting a mature, stable but declining commercial opportunity requiring defensive positioning and cost management focus.
Androgen Receptor Agonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Worked on ANDRODERM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moANDRODERM career opportunities are currently limited (0 linked jobs) and focused on commercial defense and managed care strategy rather than innovation or growth initiatives. Professionals joining the team should expect responsibility for protecting market share through payer negotiations, generic deflection, and possibly authorized generic or lifecycle management strategies.